Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model

Calcilytics are calcium‐sensing receptor (CaSR) antagonists that reduce the sensitivity of the CaSR to extracellular calcium. Calcilytics have the potential to treat autosomal dominant hypocalcemia type 1 (ADH1), which is caused by germline gain‐of‐function CaSR mutations and leads to symptomatic hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannan, Fadil M, Gorvin, Caroline M, Babinsky, Valerie N, Olesen, Mie K, Stewart, Michelle, Wells, Sara, Cox, Roger D, Nemeth, Edward F, Thakker, Rajesh V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574706/
https://www.ncbi.nlm.nih.gov/pubmed/33103030
http://dx.doi.org/10.1002/jbm4.10402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574706/
https://www.ncbi.nlm.nih.gov/pubmed/33103030
http://dx.doi.org/10.1002/jbm4.10402

Ejemplares similares